Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Immunogenicity of Cecolin 9 in Healthy Women
NCT03935204Phase 2Completed
- Sponsor
- Xiamen University
- Start
- May 2019
- Primary completion
- Oct 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Cecolin 9 in human papillomavirus infection, Cervical Cancer (CC) and condylomata acuminata (2 arms), sponsored by Xiamen University. Primary endpoints: Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates at Month 7 and Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 geometric mean concentrations at Month 7. Started May 2019; status: completed.
02
Drugs
Cecolin 9
03
Conditions
human papillomavirus infectionCervical Cancer (CC)condylomata acuminata
Beyond the preview
Go deeper on NCT03935204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03935204.